1. Home
  2. FSBW vs CRVS Comparison

FSBW vs CRVS Comparison

Compare FSBW & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FSBW
  • CRVS
  • Stock Information
  • Founded
  • FSBW 1936
  • CRVS 2014
  • Country
  • FSBW United States
  • CRVS United States
  • Employees
  • FSBW N/A
  • CRVS N/A
  • Industry
  • FSBW Banks
  • CRVS Biotechnology: Pharmaceutical Preparations
  • Sector
  • FSBW Finance
  • CRVS Health Care
  • Exchange
  • FSBW Nasdaq
  • CRVS Nasdaq
  • Market Cap
  • FSBW 324.8M
  • CRVS 305.4M
  • IPO Year
  • FSBW 2012
  • CRVS 2016
  • Fundamental
  • Price
  • FSBW $42.71
  • CRVS $5.75
  • Analyst Decision
  • FSBW Hold
  • CRVS Strong Buy
  • Analyst Count
  • FSBW 1
  • CRVS 4
  • Target Price
  • FSBW $44.00
  • CRVS $15.00
  • AVG Volume (30 Days)
  • FSBW 17.5K
  • CRVS 518.7K
  • Earning Date
  • FSBW 10-21-2025
  • CRVS 08-07-2025
  • Dividend Yield
  • FSBW 2.62%
  • CRVS N/A
  • EPS Growth
  • FSBW N/A
  • CRVS N/A
  • EPS
  • FSBW 4.15
  • CRVS N/A
  • Revenue
  • FSBW $139,676,000.00
  • CRVS N/A
  • Revenue This Year
  • FSBW $9.62
  • CRVS N/A
  • Revenue Next Year
  • FSBW $5.35
  • CRVS N/A
  • P/E Ratio
  • FSBW $10.28
  • CRVS N/A
  • Revenue Growth
  • FSBW 0.61
  • CRVS N/A
  • 52 Week Low
  • FSBW $34.61
  • CRVS $2.54
  • 52 Week High
  • FSBW $49.15
  • CRVS $10.00
  • Technical
  • Relative Strength Index (RSI)
  • FSBW 61.80
  • CRVS 65.10
  • Support Level
  • FSBW $41.40
  • CRVS $5.28
  • Resistance Level
  • FSBW $42.89
  • CRVS $5.64
  • Average True Range (ATR)
  • FSBW 1.14
  • CRVS 0.30
  • MACD
  • FSBW 0.32
  • CRVS 0.03
  • Stochastic Oscillator
  • FSBW 95.42
  • CRVS 77.70

About FSBW FS Bancorp Inc.

FS Bancorp Inc is the holding company of 1st Security Bank, a diversified lender with a focus on the origination of commercial real estate, one-to-four-family, and home equity loans, consumer loans, including a variety of indirect home improvement (fixture secured loans), and marine loans, and commercial business loans. The company has two operating segments; The commercial and consumer banking segment provides diversified financial products and services to its commercial and consumer customers through Bank branches, automated teller machines, online banking platforms, mobile banking apps, and telephone banking; and The home lending segment originates one-to-four-family residential mortgage loans for sale in the secondary markets as well as loans held for investment.

About CRVS Corvus Pharmaceuticals Inc.

Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).

Share on Social Networks: